Vicinitas Therapeutics

Vicinitas Therapeutics is a biotechnology company founded in 2022 and based in South San Francisco, California.

It was established through a collaboration between the University of California, Berkeley, and the Novartis Institutes for BioMedical Research. The company focuses on developing innovative therapeutic solutions for challenging targets known as "undruggable" proteins, particularly in the fields of oncology and monogenic disorders. The core of Vicinitas' work is its proprietary DUBTAC platform, which enables the stabilization of proteins that are often degraded by the cell's ubiquitin-proteasome system. This technology aims to restore the function of essential proteins, offering potential treatments for diseases such as cancer, cystic fibrosis, and Stargardt disease. Vicinitas has successfully raised $65 million in funding, positioning itself for impactful advancements in drug discovery and development.